

SCHEDULE 2 - TEMPLATE



Slovakia € - Year 2023 - Date: June 2024

	Full Name  <i>(Art. 1.01)</i>	HCPs: City of Principal Practice HCOs: city where registered  <i>(Art. 3)</i>	Country of Principal Practice  <i>(Schedule 1)</i>	Principal Practice Address  <i>(Art. 3)</i>	Unique country identifier <i>OPTIONAL</i>  <i>(Art. 3)</i>	Donations and Grants to HCOs <i>(Art. 3.01.1.a)</i>	Contribution to costs of Events <i>(Art. 3.01.1.b &amp; 3.01.2.a)</i>			Fee for service and consultancy <i>(Art. 3.01.1.c &amp; 3.01.2.c)</i>		TOTAL <i>OPTIONAL</i>	
							Sponsorship agreements with HCOs / third parties appointed by HCOs to manage an Event	Registration Fees	Travel & Accommodation	Fees	Related expenses agreed in the fee for service or consultancy contract, including travel & accommodation relevant to the contract		
HCPs	<i>INDIVIDUAL NAMED DISCLOSURE - one line per HCP (i.e. all transfers of value during a year for an individual HCP will be summed up; itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate)</i>												
	<i>OTHER, NOT INCLUDED ABOVE - where information cannot be disclosed on an individual basis for legal reasons</i>												
	Aggregate amount attributable to transfers of value to such Recipients - <i>Art. 3.02</i>						N/A	N/A			2,378		2,378
	Number of Recipients in aggregate disclosure - <i>Art. 3.02</i>						N/A	N/A			1		1
<i>% of the number of Recipients included in the aggregate disclosure in the total number of Recipients disclosed - Art. 3.02</i>						N/A	N/A			100%		100%	
HCOs	<i>INDIVIDUAL NAMED DISCLOSURE - one line per HCO (i.e. all transfers of value during a year for an individual HCO will be summed up; itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate)</i>												
	<i>OTHER, NOT INCLUDED ABOVE - where information cannot be disclosed on an individual basis for legal reasons</i>												
	Aggregate amount attributable to transfers of value to such Recipients - <i>Art. 3.02</i>												
	Number of Recipients in aggregate disclosure - <i>Art. 3.02</i>												
<i>% of the number of Recipients included in the aggregate disclosure in the total number of Recipients disclosed - Art. 3.02</i>													
R & D	<b>AGGREGATE DISCLOSURE</b>												
	Transfers of Value re Research & Development as defined - <i>Article 3.04 and Schedule 1</i>												